[Angiogenesis inhibitors (bevacizumab - ranibizumab) in neovascular glaucoma and corneal neovascularization]

Oubiña M, Pichon-Riviere A,Gentile C Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32017000272
Authors' recommendations: Evidence of moderate quality shows that bevacizumab, when compared with placebo, might have some effectiveness in reducing intraocular pressure in patients with neovascular glaucoma, although the information is uncertain. When compared with mitomycin c as adjuvant to trabeculectomy, no significant differences were observed in terms of intraocular pressure reduction. Evidence of low quality shows that ranibizumab would not significantly reduce intraocular pressure when used in patients with neovascular glaucoma. The clinical practice guidelines surveyed consider bevacizumab as an option among others including photodynamic therapy or surgery. No guidelines recommending the use of ranibizumab were found. The United States health sponsors consulted cover bevacizumab in patients with neovascular glaucoma. Only one of them covers ranibizumab for this indication. As regards corneal neovascularization treatment, very low-quality evidence shows that bevacizumab might reduce the neovascularization area, however this would not necessarily mean clear clinical benefits and did not prove to be superior to other therapeutic alternatives such as photodynamic therapy. No studies comparing ranibizumab with usual treatments were found. That is why the clinical practice guidelines would not consider it as an alternative and the United States health sponsors consulted do not cover it because they consider these treatments as experimental.
Project Status: Completed
Year Published: 2017
URL for published report: www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Corneal Neovascularization
  • Glaucoma, Neovascular
  • Humans
  • Ranibizumab
  • Vascular Endothelial Growth Factor A
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.